Integer Holdings Corp
Integer Holdings, headquartered in Plano, Texas, is a medical device contract development and manufacturing organization serving the Cardio and Vascular, Neuromodulation, and Cardiac Rhythm Management markets. Its customers are primarily large multinational medical device original equipment manufacturers and their subsidiaries. Integer operates one reportable segment and has three principal product lines: Cardio & Vascular; Cardiac Rhythm Management & Neuromodulation; and Other Markets. Its brands include Greatbatch Medical and Lake Region Medical. Integer designs, develops and manufactures medical device components, subassemblies, assemblies and finished devices. Its offerings include catheter- and wire-based technologies, vascular and electrophysiology devices, cardiac rhythm management and neuromodulation systems, and products for minimally invasive and general surgery, orthopedics and portable medical markets. It also provides engineering, testing, regulatory and clinical services. Integer sells primarily directly to customers, including custom products made to OEM specifications and device solutions ready for market distribution.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ITGR in the last 7 days.
No SEC Form 4 filings for $ITGR in the last 30 days.
See all $ITGR insider activity →Integer Holdings reported Q3 Non-GAAP EPS of $1.34, missing estimates by $0.34, and revenue of $449.66M, missing by $7.49M. Cardio & Vascular sales declined 5% year-over-year to $263M. According to the company, the results reflect previously communicated challenges.
Integer Holdings Corp (ITGR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Integer Holdings Corporation Reports Third Quarter 2026 Results PLANO, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended October 2, 2026. Third Quarter 2026 Highlights (compared to Thi
Integer Holdings stockholders approved the proposed acquisition by KKR. The deal is supported by debt financing preparations led by Citigroup. Integer's stock has seen a 61.55% increase year-to-date, according to the company.
Recent ITGR coverage spans mergers & acquisitions, earnings and corporate actions.
Earnings miss suggests weaker performance and may trigger sell pressure.
Quarterly earnings miss and updated guidance cause negative sentiment.
Positive catalyst for Integer as deal approval removes uncertainty; potential upside as acquisition premium is priced in.
Deal momentum improves as the required shareholder approvals were secured, reducing one key closing condition risk while keeping regulatory approvals as the main remaining hurdle.
Deal approval removes regulatory uncertainty and clears a major corporate action, likely supporting a price rally for Integer.
AlphAI scores every news story that mentions ITGR with an AI model for sentiment and relevance, and aggregates insider trades from Integer Holdings Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Integer Holdings reported Q3 Non-GAAP EPS of $1.34, missing estimates by $0.34, and revenue of $449.66M, missing by $7.49M. Cardio & Vascular sales declined 5% year-over-year to $263M. According to the company, the results reflect previously communicated challenges.
Integer Holdings Corp (ITGR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Integer Holdings Corporation Reports Third Quarter 2026 Results PLANO, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended October 2, 2026. Third Quarter 2026 Highlights (compared to Thi
Integer Holdings stockholders approved the proposed acquisition by KKR. The deal is supported by debt financing preparations led by Citigroup. Integer's stock has seen a 61.55% increase year-to-date, according to the company.
Integer Holdings Corp (ITGR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Exhibit 99.1 Integer Holdings Corporation Stockholders Approve Proposals in Connection with KKR’s Proposed Acquisition of Integer PLANO, Texas, October 21, 2026 (GLOBE NEWSWIRE) – Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”) and Armstrong Parent, Inc. (“
Integer Holdings (NYSE:ITGR) stockholders approved its $4.7B acquisition by Armstrong Parent, with 99.95% of votes in favor. The deal, signed in August 2026, is expected to close by year-end, pending regulatory approvals. Integer is a medical device manufacturer.
Integer Holdings (ITGR) will hold a stockholder vote on Oct. 21 regarding a KKR-backed merger. The company faces three lawsuits alleging proxy statement deficiencies and has added disclosures to mitigate risks. Goldman Sachs' DCF analysis estimates a per-share range of $98.93–$140.68, assuming ~35M diluted shares and ~$1.257B debt.
Integer Holdings Corp (ITGR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events As previously disclosed, on August 2, 2026, Integer Holdings Corporation, a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement,” and the transactions contemplated thereby, the “Transaction”), by and amo
Heartland Value Fund's Q3 2026 letter notes Integer Holdings (ITGR) gained 61.41% YTD, closing at $126.52. KKR agreed to acquire ITGR for $127/share, a 70%+ premium to the fund's average cost. ITGR's market cap is $4.3B. The fund underperformed in Q3 due to macroeconomic concerns, with the Russell 2000 Value Index down 4.91%.
STAAR Surgical (STAA) reported Q2 revenue of $93.54M, up 111% YoY, beating estimates by 3.3%. Inspire Medical (INSP) saw revenue drop 7.6% YoY but beat estimates, raising guidance. Enovis (ENOV) reported $582.8M in revenue, up 3.2%, missing full-year EPS guidance. Integer (ITGR) and Haemonetics (HAE) also reported Q2 results, with ITGR up 4.4% and HAE up 21.7% since reporting.
Integer (ITGR) announced its 2.125% convertible senior notes due 2028 can be converted in Q4 2026. The conversion price is set at $87.20 per share, with a rate of 11.4681 shares per $1,000 principal. Conversion is conditional on the company's stock meeting a 130% price threshold, according to the company.
